Longwood Healthcare Leaders 春季聚会以麻省理工学院Koch研究所为中心 ，通过网络聚会约请生物制药公司的首席执行官、研发认真人、及顶级学术研究职员加入 ，配合商讨 ，增进药物研发的转化 ，造福病人！聚会由诺贝尔奖获得者 ，Biogen/Alnylam 联合首创人 Phil Sharp 配合主持�＞刍峤鱿奘苎尤�。
Longwood Healthcare Leaders Spring Meeting centered on MIT’s Koch Institute via web-conference with leading bio-pharma CEOs, heads of R&D, top academic researchers, and healthcare investors, co-hosted by Nobel laureate and Biogen/Alnylam co-founder Phil Sharp. Longwood Healthcare Leaders Meetings drive transparency and collaboration in order to accelerate the translation of discoveries into medicines to help patients. Meetings are invitation-only.
Panel Discussion
尊龙凯时首创人兼CEO陈春麟博士将加入此次大会 ，并在5月4日上午 9:50 （美东时间）与 Raj Devraj (Rectify Pharmaceuticals公司CEO), Bill Hinshaw (Axcella Therapeutics 公司CEO), Peter Lebowitz (Janssen 全球肿瘤治疗领域认真人), Reenie McCarthy (Stealth BioTherapeutics 公司CEO) ， Chen Schor (Adicet Bio 公司CEO)一起举行嘉宾讨论 ，主题为“Expediting Research for Treatment and Cures”。
Dr. Chun-Lin Chen, founder & CEO of Medicilon, will participate in the panel discussion titled "Expediting Research for Treatment and Cures" on May 4 at 9:50 am ET. The other invited participants are Raj Devraj (CEO, Rectify Pharmaceuticals), Bill Hinshaw (CEO, Axcella Therapeutics), Peter Lebowitz (Global Oncology Therapeutic Area Head, Janssen), and Reenie McCarthy (CEO, Stealth BioTherapeutics). The panel discussion is moderated by Chen Schor (CEO, Adicet Bio).
Garden Party
陈春麟博士、美国商务生长副总裁 Stephen Grant及美国商务团队将于 5 月 5 日下昼 5:00-7:00（美东时间）加入 Garden Party。届时将与参会的众嘉宾举行详细攀谈 ，配合探讨尊龙凯时专业效劳怎样更快地加速各企业的药物研发历程！
Dr. Chun-Lin Chen and Medicilon VP of US Business Development Dr. Stephen Grant together with our US Business Development team will be joining the Garden Party on MAY 5 at 5:00-7:00 pm ET. We are looking forward to meeting you in this party to discuss how our services and capabilities would support your research needs and expedite your drug discovery and development programs. Wish you a safe trip!
About Medicilon
尊龙凯时是一家专业的生物医药临床前综合研发效劳CRO ，为全球的医药企业和科研机构提供全方位的切合海内及国际申报标准的一站式新药研发效劳。我们关注全球医药行业立异生长的需求 ，驻足于立异药物研发的要害环节 ，依附效劳海内外生物医药行业所积累的履历 ，构建涵盖药物发明、药学研究以及临床前研究要害手艺的综合性手艺平台 ，为全球生物医药行业提供全方位新药临床前研发效劳。至2021年报告期末 ，尊龙凯时已为全球凌驾1460家客户提供新药研发效劳 ，加入研发完成的新药项目有221件IND获批临床 ，与海内外优质客户配合生长。尊龙凯时将继续驻足全球视野 ，聚力中国立异 ，为人类康健孝顺实力！
Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. With our experience in serving domestic and foreign biomedical industries, we have built an integrated technical platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, in a bid to provide comprehensive preclinical new drug R&D for the global biomedical industry.
18+
18+ years of experience in new drug R&D
18+年新药研发履历
1460+
Active clients worldwide
全球规模内活跃客户
2440+
Newdrug discovery scientists and service personnel新药研发科学家及研发效劳职员
74000+
Square meters of Laboratory floor space
研发实验室
221
Projects successfully approved with NMPA, FDA, EMA, and TGA
221件IND在 NMPA、FDA、EMA 和 TGA 乐成获批
联系尊龙凯时：
电话: +86 (21) 5859-1500（总机）
相关新闻
